

Meningococcal Disease Vaccine Industry 2025: Government Immunization Programs Fueling The Growth Of The Market

The Business Research Company's Meningococcal Disease Vaccine Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, June 18, 2025 /EINPresswire.com/ -- The Business Research Company's Latest Report



Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

What Is The Growth Trajectory Of The Meningococcal Disease Vaccine Market? Recent data shows a rapid growth in the <u>meningococcal disease vaccine market size</u>. The market,

"

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights -Market Sizing & Forecasts Through 2034" *The Business Research Company* which stood at a valuation of \$2.37 billion in 2024, is projected to reach \$2.62 billion in 2025 at an impressive compound annual growth rate CAGR of 10.4%. This monumental growth can be attributed to factors such as increase in meningococcal disease cases, enhancing vaccine manufacturing capabilities, strengthening global health partnerships, inclusion in national immunization schedules, and the concerted efforts by various health organizations around the globe.

Will The Meningococcal Disease Vaccine Market Growth

Continue Throughout The Decade?

Fast-forward a few more years and analysts predict that the meningococcal disease vaccine market size will continue its impressive upward trajectory—expected to expand to \$3.83 billion by 2029 at a CAGR of 10.0%. The market's acceleration is anticipated to be driven by the expanding target age groups, entry of new market players, stockpiling of vaccines by governments and health agencies in preparation for potential outbreaks, increasing public awareness, and a stronger emphasis on preventive healthcare. A glimpse into the forecast period indicates major trends, including advancements in vaccine technology, growth in the

development of multivalent, conjugate, and protein-based vaccines, as well as increasing research and development for mRNA and innovative thermostable formulations.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=24317&type=smp

What's Propelling This Potent Growth In The Meningococcal Disease Vaccine Market? Among the key market drivers expected to fuel the growth of the meningococcal disease vaccine market are the increasing initiatives for government immunization programs. These programs—offering free or low-cost vaccines—are crucial in protecting communities against infectious diseases. With an increased focus on the prevention of infectious diseases and reducing the burden on healthcare systems through comprehensive vaccination coverage, government immunization programs are experiencing substantial growth. These initiatives not only drive the growth of meningococcal vaccines by expanding access and increasing vaccination rates, but they also play a pivotal role in boosting awareness while reducing the incidence of diseases. The immunization programs create demand for vaccines by mandating vaccinations and promoting public health. Case in point, in April 2024, the Pan American Health Organization launched the 22nd Vaccination Week in the Americas, during which over 65 million doses were administered in a concerted effort to increase vaccination coverage. The program focused on combating misinformation, enhancing vaccine access, and increasing community engagement with tailored campaigns.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-globalmarket-report

Which Companies Are Leaders In The Meningococcal Disease Vaccine Market? Key industry players contributing to the growth of the meningococcal disease vaccine market include Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., and Incepta Pharmaceuticals Ltd., among others.

What Are The Emerging <u>Trends Within The Meningococcal Disease Vaccine Market</u>? A notable trend in the industry includes the concerted focus of major companies on the development of advanced products such as the pentavalent meningococcal vaccines. These cutting-edge vaccines target five major serogroups of Neisseria meningitidis in a single dose, thus eliminating the need for multiple vaccinations, improving compliance rates, and aiding disease prevention efforts. As a demonstration, Pfizer Inc., a recognized US-based biopharmaceutical company, secured the approval for PENBRAYA from the Food and Drug Administration in October 2023. The innovative vaccine, the first of its kind in the market, provides protection against the five most common serogroups A, B, C, W, and Y of Neisseria meningitidis and has the potential to simplify vaccination schedules by reducing the number of doses required for full protection.

How is The Meningococcal Disease Vaccine Market Classified? Precisely, the meningococcal disease vaccine market is segmented primarily based on:

1 Vaccine Type: Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines.

2 Age Group: Infants, Children, Adults, Older Adults.

3 Indication: Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response.

4 Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels.

5 End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users.

It also includes subsegmentation based on vaccine type, offering further categorization for more granular data.

What Are The Regional Insights Into The Meningococcal Disease Vaccine Market? In 2024, North America emerged as the largest region in the meningococcal disease vaccine market. However, during the forecast period, Asia-Pacific is expected to experience the fastest growth. Other regions covered in this report include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Pediatric Vaccine Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report</u>

DTP Vaccines Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

About The Business Research Company

With over 15000+ reports across 27 industries spanning 60+ geographies, The Business Research Company has built its reputation on offering comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets and unparalleled insights from industry leaders, you can secure the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <u>https://www.thebusinessresearchcompany.com/</u>

Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: <u>https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: LinkedIn Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/823278649

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.